A cost-effectiveness analysis of immunotherapy with SQ allergen extract for patients with seasonal allergic rhinoconjunctivitis in selected European countries

Current Medical Research and Opinion

Volumn 23, Issue 5, 2007, Pages 1113-1120

  Keiding, Hans ^a   Jorgensen, Kasper P ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b TPR Group   (Belgium)

Author keywords

Cost effectiveness; Immunization therapy; Rhinoconjunctivitis

Indexed keywords

ACRIVASTINE; ALLERGEN; ALUTARD; ANTIHISTAMINIC AGENT; CETIRIZINE; CROMOGLYCATE DISODIUM; DESLORATADINE; FLUTICASONE PROPIONATE; LEVOCETIRIZINE; PLACEBO; PREDNISOLONE; SALBUTAMOL; STEROID;

ADULT; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; EUROPE; FEMALE; FOLLOW UP; GEOGRAPHIC DISTRIBUTION; HEALTH ECONOMICS; HUMAN; IMMUNOTHERAPY; MALE; MEDICAL STAFF; MULTICENTER STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SEASONAL ALLERGIC CONJUNCTIVITIS;

ADULT; COST-BENEFIT ANALYSIS; DESENSITIZATION, IMMUNOLOGIC; EUROPE; FEMALE; HUMANS; MALE; MIDDLE AGED; PLANT EXTRACTS; POACEAE; RHINITIS, ALLERGIC, SEASONAL;

EID: 34249094514     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X187865     Document Type: Article

References (22)

1. Levy ML, Sheikh A, Walker S, Woods A. Should UK allergy focus on primary care? BMJ 2006;332:1347-8
2. Varney VA, Gaga M, Frew AJ, Aber VR. Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs. BMJ 1991;302:265-269
3. Walker SM, Pajno GB, Lima MT, et al. Grass pollen immunotherapy for seasonal rhinitis and asthma: a randomized controlled trial. J Allergy Clin Immunol 2001,107:87-93
4. Jacobsen L, Nuchel Petersen B, Wihl JA, Lowenstein H, et al. Immunotherapy with partially purified and standardized tree pollen extracts. IV. Results from long-term (6-year) follow-up. Allergy 1997;52:914-20
5. Mosbech H, Østerballe O. Does the effect of immunotherapy last after termination of treatment? Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999;341:523-9
6. Durham SR, Waljer SM, Varga EM, Jacobson MR, et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999;341:468-75
7. Hedlin G, Heilborn H, Lilja G, Norrlind K, et al. Long-term follow-up of patients treated with a three-year course of cat or dog immunology. J Allergy Clin Immunol 1995;96:879-85
8. Möller C, Dreborg S, Ferdousi HA, Halken S, et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis. The PAT-study. J Allergy Clin Immunol 2002;109:251-6
9. Rakemann FM, Edwards RN. Asthma in children. A follow-up study of 688 patients after an interval of twenty years. N Engl J Med 1952;246:815-23
10. Linna O, Kokkonen J, Lukin M. A 10-year prognosis for child-hood allergic rhinitis. Acta Paediatr 1992;81:100-2
11. Berggren F, Hjelmgren J, Lindgren B. Differences in healthcare utilisation and workdays lost between individuals with and without asthma. Appl Health Econ Health Policy 2003;3:165-70
12. World Health Organization (WHO) Allergen immunotherapy: therapeutic vaccines for allergic diseases. Allergy 1998;53:1-42
13. Frew AJ, Powell RJ, Corrigan CJ Durham SR. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006;117:319-25
14. Pedersen KD. Allergibehandling. En samfundsøkonomisk analyse i Århus Amt (In Danish: Allergy treatment. An economic analysis in Århus County). MPH thesis. Faculty of Medicine, Århus University
15. Cost-effectiveness of immunotherapy with Alutard 100,000 SQ-U in patients with seasonal allergic rhinoconjunctivitis, Reports (a) Austria, (b) Denmark, (c) Finland, (d) Germany, (e) Netherlands, (f) Sweden. Muusmann Research & ALK-Abelló, 2004
16. Bousquet J, Demarteau N, Mullol J, van den Akker-van Marle ME, et al. Costs associated with persistent allergic rhinitis are reduced by levocetirizine. Allergy 2005;60:788-94
17. National Institute for Clinical Excellence (NICE). Guide to the Methods of Technology Appraisal, NHS, April 2004
18. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997;35:1095-108
19. Pedersen KM, Wittrup-Jensen K, Brooks R, Gudex C. Værdisæ tning af sundhed. Teori om kvalitetsjusterede leveår (In Danish: Valuation of health. Theory of quality adjusted life years), Syddansk Universitetsforlag, Odense 2003
20. Brown R, Turk F, Dale P, Bousquet J. Cost-effectiveness of omalizumab in patients with severe persistent allergic asthma. Allergy 2007;62:149-53
21. Meltzer EO. Quality of life in adults and children with allergic rhinitis. J Allergy Clin Immunol 2001;108:S45-53
22. Pajno GB, Barberio G, De Luca F, Morabito L, et al. Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin Exp Allergy 2001;31:1392-7